Sign In
Buy VVOS
$0.466
+0.0641 (+15.94%)
At Close: Jun 23, 2026
Vivos and Streeterville Extend Timeframe of Financing Agreement and Reaffirm Commitment to Convert Debt Into Common Stock and Perpetual Preferred Equity
Vivos Therapeutics Announces Intent to File a Registration Statement for a Proposed Rights Offering
08:30am, Thursday, 11'th Jun 2026
LITTLETON, Colo., June 11, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), a leading medical device and healthcare services company focused on the
Vivos Announces Collaboration Agreement with Florida Cardiology Group to Extend Sleep Apnea and Insomnia Diagnosis and Treatment to Cardiovascular Patients
Vivos Therapeutics To Participate in the Small Cap Showcase & WTR Insights on June 9, 2026
01:39pm, Monday, 08'th Jun 2026
LITTLETON, Colo., June 08, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company'') (NASDAQ: VVOS), a leading medical device and healthcare services company focused on the t
Vivos Announces Binding Agreement for Senior Debt-to-Equity Exchange of Up to $4.5 Million from Streeterville Capital to Support Continued Nasdaq Listing
Vivos Therapeutics, Inc. (VVOS) Q1 2026 Earnings Call Transcript
04:10am, Thursday, 21'st May 2026
Vivos Therapeutics, Inc. (VVOS) Q1 2026 Earnings Call Transcript
Vivos Therapeutics Reports First Quarter 2026 Financial Results and Provides Operational Update
04:10pm, Wednesday, 20'th May 2026
Year-over-year revenue increased 70%, reflecting contribution from Vivos' acquisition of The Sleep Center of Nevada Management to Host Conference Call today at 5:00 pm ET LITTLETON, Colo., May 20, 202
Analysts see 200%+ upside in these 3 high-risk stocks: here's why?
11:53am, Saturday, 09'th May 2026
Some of Wall Street's biggest upside calls are not sitting in the mega-cap names. They are hiding in small, volatile stocks with thin balance sheets, limited operating history and one big event ahead.
Vivos Therapeutics Q4 Earnings Call Highlights
03:31am, Friday, 17'th Apr 2026
Vivos Therapeutics (NASDAQ: VVOS) executives told investors the company's shift toward a medical provider-focused model, anchored by the June 2025 acquisition of the Sleep Center of Nevada (SCN), drov
Vivos Therapeutics, Inc. (VVOS) Q4 2025 Earnings Call Transcript
06:41pm, Wednesday, 15'th Apr 2026
Vivos Therapeutics, Inc. (VVOS) Q4 2025 Earnings Call Transcript
Vivos Therapeutics Reports Full Year 2025 Financial Results
04:20pm, Wednesday, 15'th Apr 2026
Full Year 2025 revenue increased 16% Integration of The Sleep Center of Nevada and shift in business model support path to improved revenues, margins and cash flow Management to Host Conference Call t
Vivos Therapeutics Schedules Release of Full Year 2025 Financial Results and Conference Call
08:45am, Wednesday, 15'th Apr 2026
LITTLETON, Colo., April 15, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. ("Vivos" or the "Company") (NASDAQ: VVOS), a leading medical device and healthcare services company focused on the treatme
Vivos Therapeutics, Inc. (NASDAQ:VVOS) Short Interest Update
02:19am, Wednesday, 15'th Apr 2026
Vivos Therapeutics, Inc. (NASDAQ: VVOS - Get Free Report) was the target of a large decline in short interest during the month of March. As of March 31st, there was short interest totaling 316,118 sha
Vivos Therapeutics Completes Private Placement with Existing Private Equity Investor, New Seneca Partners
08:45am, Tuesday, 07'th Apr 2026
LITTLETON, Colo., April 07, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. ("Vivos" or the "Company") (NASDAQ: VVOS), a leading medical device and healthcare services company focused on the treatme
Vivos Therapeutics (NASDAQ:VVOS) Major Shareholder Michael Skaff Purchases 1,353,625 Shares
04:48am, Friday, 03'rd Apr 2026
Vivos Therapeutics, Inc. (NASDAQ: VVOS - Get Free Report) major shareholder Michael Skaff bought 1,353,625 shares of the company's stock in a transaction on Tuesday, March 31st. The stock was bought a
